Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
182 hedge funds and large institutions have $1.83B invested in Aerie Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 78 increasing their positions, 47 reducing their positions, and 19 closing their positions.
88% more call options, than puts
Call options by funds: $33.7M | Put options by funds: $18M
66% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 47
58% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 19
6% more funds holding
Funds holding: 172 → 182 (+10)
1% more capital invested
Capital invested by funds: $1.81B → $1.83B (+$16.8M)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$84.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$36.3M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$15.2M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$21.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.5M |
| 3 |
DM
Deerfield Management
New York
|
-$17.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$17.6M |
| 5 |
BC
Broadfin Capital
New York
|
-$13.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Envestnet Asset Management
Chicago,
Illinois
| – | -$22K | -414 | Closed |
|
AERI Hedge Fund Activity: Q3 2017 in Review
182 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2017, worth a combined $1.83B — up 0.93% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new AERI positions and 19 closed out — a net gain of 11 holders — while 78 added to existing stakes and 47 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $84.7M. The largest seller was OrbiMed, cutting an estimated $21.5M.
- 182 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2017, up from 172 in Q2 2017.
- Funds reported $1.83B of Aerie Pharmaceuticals stock for Q3 2017, up 0.93% quarter-over-quarter.
- 30 funds opened new Aerie Pharmaceuticals positions in Q3 2017 and 19 closed out, a net change of +11 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2017 was Wellington Management Group, an estimated $84.7M added.
- The largest Aerie Pharmaceuticals seller in Q3 2017 was OrbiMed, an estimated $21.5M sold.
Based on aggregated 13F filings for Q3 2017.